Notes from the Field: Identifying Risk Behaviors for Invasive Group A Streptococcus Infections Among Persons Who Inject Drugs and Persons Experiencing Homelessness — New Mexico, May 2018
Weekly / March 1, 2019 / 68(8);205–206
Sandra J. Valenciano, MD1,2; Chelsea McMullen, MPH3; Salina Torres, PhD3; Chad Smelser, MD3; Almea Matanock, MD2; Chris Van Beneden, MD2 (View author affiliations)View suggested citation
Views equals page views plus PDF downloads
- pdf icon [PDF]
In the spring of 2018, the New Mexico Department of Health (NMDOH) contacted CDC about an increase in the number and prevalence of invasive group A Streptococcus (GAS) infections reported through New Mexico’s Active Bacterial Core surveillance (ABCs) system. From 2013 to 2017, the annual rate of invasive GAS infections increased approximately 120%, from 6.8 to 14.9 per 100,000 persons, approximately double the estimated national rate (1,2). In New Mexico, the prevalence of injection drug use (IDU) reported in the medical charts of patients with invasive GAS infection during this period (1,108 patients) increased approximately 200%, from 6.4% (nine of 141 invasive GAS infections) to 20.1% (62 of 308 invasive GAS infections), and the prevalence of reported homelessness among persons with invasive GAS infections increased 125%, from 3.6% (five of 141) to 8.1% (25 of 308). IDU is a known risk factor for GAS infections; however, specific behaviors causing the recent increase in the prevalence of IDU among patients with GAS infection are unknown. Although recent outbreaks of invasive GAS infection among persons experiencing homelessness have been reported in Canada, Europe, Arizona, and Alaska, homelessness is not a well-defined risk factor for invasive GAS infection in the United States; therefore, identifying specific behaviors that might increase the risk for infection in this group might help inform prevention efforts (3–6). NMDOH requested CDC assistance in characterizing GAS disease and specific high-risk behaviors among persons who inject drugs and persons experiencing homelessness to recommend potential public health interventions to reduce disease risk and transmission among these populations.
NMDOH and CDC received daily laboratory lists to identify patients hospitalized with GAS infection during May 1–23, 2018, at one of four hospital systems in Albuquerque and Santa Fe. A case was defined as illness with GAS cultured from any site (excluding throat and urine cultures) in an adult aged 18–65 years. Identified patients were interviewed using a standardized questionnaire focusing on known risk factors (e.g., exposure to ill children; crowding; IDU; and presence of underlying medical conditions, such as diabetes, chronic liver disease, and skin breakdown) and potential risk factors (e.g., poor hygiene, injection practices, and sharing of drug paraphernalia) for GAS infection and abstracted these data from their medical charts. The team interviewed personnel from organizations that care for persons who inject drugs and those experiencing homelessness to generate hypotheses for the increase in GAS infections among these groups.
Thirty-five patients with GAS infection were identified; 26 (74%) could be contacted and are included in the analysis. The mean patient age was 48 years (range = 24–63 years); 17 (65.4%) were male, seven (26.9%) were American Indian, and 15 (57.7%) identified as Hispanic/Latino (Table). Approximately half of the cases were identified as cellulitis, and approximately one third were identified as abscesses. Among known risk factors for GAS infections, skin breakdown, either recent (21; 80.8%) or current (20; 76.9%), was reported most frequently. Fifteen (57.7%) patients had been seen by a wound care provider in the month preceding their admission. Eight (30.8%) interviewed patients were experiencing homelessness, and three (11.5%) injected drugs. Persons experiencing homelessness did not report staying in crowded settings, such as shelters. However, recent or current skin breakdown was reported by six and five persons experiencing homelessness, respectively, and six reported having seen a wound care provider before their hospital admission. Reported injected drugs included heroin, cocaine, and methamphetamines, alone or in combination. All three persons who injected drugs reported injecting multiple times in the same day, two reported injecting multiple times with the same needle, and one reported sharing needles and licking the needle before injection.
Among 15 interviewed providers, barriers to good hygiene and appropriate skin care in persons experiencing homelessness and persons who inject drugs were noted, including limited access to clean running water, showers, or bathrooms; poverty; or alcohol and drug addiction. To prevent GAS infection, seven providers suggested developing educational tools for persons experiencing homelessness, persons who inject drugs, and personnel working with these populations.
The increased number of invasive GAS cases occurring among persons experiencing homelessness and those who inject drugs might have contributed to the overall increase in GAS in New Mexico from 2013 to 2017. However, the small number of persons interviewed for this study limit the ability to draw significant conclusions regarding specific risk behaviors that might increase the risk for GAS infection among these populations. Replicating this pilot investigation at other sites might help identify specific risk behaviors for acquiring GAS among these vulnerable populations. Because most patients had previous encounters with the health care system, it is important for providers who care for persons who inject drugs or are experiencing homelessness to be aware of the risk for severe GAS infections in these groups. In addition, educational material, that describes GAS symptoms, good hygiene and skin care, and safe injection practices, could benefit both patients and providers.
Robyn Cree, Epidemic Intelligence Service, National Center on Birth Defects and Disabilities, CDC; David Siegel, Epidemic Intelligence Service, National Center for Chronic Disease Prevention and Health Promotion, CDC; Faisal Reza, Public Health Informatics Fellowship Program, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Jennifer Onukwube, Michael W. Spiller, Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC; Michael Landen, New Mexico Department of Health; Lisa M. Butler, Robert Mansmann, Sarah A. Khanlian, Kathy M. Angeles, University of New Mexico; Karissa Culbreath, TriCore Reference Laboratory Infectious Disease Department, Albuquerque, New Mexico; Anita Córdova, Albuquerque Health Care for the Homeless, Albuquerque, New Mexico.
Corresponding author: Sandra J. Valenciano, firstname.lastname@example.org, 404-718-6859.
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- CDC. 2015. Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network, group A Streptococcus—2015. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/abcs/reports-findings/survreports/gas15.pdfpdf icon
- CDC. 2016. Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network, group A Streptococcus, 2016. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/abcs/reports-findings/survreports/gas16.pdfpdf icon
- Athey TB, Teatero S, Sieswerda LE, et al. High incidence of invasive group A Streptococcus disease caused by strains of uncommon emm types in Thunder Bay, Ontario, Canada. J Clin Microbiol 2016;54:83–92. CrossRefexternal icon PubMedexternal icon
- Bundle N, Bubba L, Coelho J, et al. Ongoing outbreak of invasive and non-invasive disease due to group A Streptococcus (GAS) type emm66 among homeless and people who inject drugs in England and Wales, January to December 2016. Euro Surveill 2017;22:30446. CrossRefexternal icon PubMedexternal icon
- Engelthaler DM, Valentine M, Bowers J, et al. Hypervirulent emm59 clone in invasive group A Streptococcus outbreak, southwestern United States. Emerg Infect Dis 2016;22:734–8. CrossRefexternal icon PubMedexternal icon
- Mosites E, Frick A, Gounder P, et al. Outbreak of invasive infections from subtype emm26.3 group A Streptococcus among homeless adults—Anchorage, Alaska, 2016–2017. Clin Infect Dis 2018;66:1068–74. CrossRefexternal icon PubMedexternal icon
Suggested citation for this article: Valenciano SJ, McMullen C, Torres S, Smelser C, Matanock A, Van Beneden C. Notes from the Field: Identifying Risk Behaviors for Invasive Group A Streptococcus Infections Among Persons Who Inject Drugs and Persons Experiencing Homelessness — New Mexico, May 2018. MMWR Morb Mortal Wkly Rep 2019;68:205–206. DOI: http://dx.doi.org/10.15585/mmwr.mm6808a5external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to email@example.com.